BioSpace News Archive

Liminal BioSciences Inc., confirms that following close of markets on April 4, 2023, the Board of Directors of the Company received a non-binding proposal from Structured Alpha LP outlining a potential transaction to acquire all of the issued and outstanding common shares of the Company that SALP does not currently own for US$7.50 in cash per common share.

Aeterna Zentaris Inc. today announced that sales of Macrilen® (macimorelin) will be temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency (“AGHD”), effective May 23, 2023 and until anticipated re-launch with an alternate commercialization partner.

Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce the presentation of five posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles, California, May 16 to 20, 2023.

ProSomnus, Inc. (“the Company”) (NASDAQ: OSA) today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent serial number (USPN) 11,617,677 on April 4, 2023, an addition to a portfolio of several issued U.S. patents covering the Company’s iterative titration technology featured in its FDA-cleared and patient-preferred Precision Oral Appliance Therapy (OAT) devices.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that Esther Rajavelu has resigned from her position as chief financial officer and treasurer effective April 21, 2023.

AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today positive results from a Phase 2a clinical trial of AIT-101 (LAM-002A)1 in patients with C9ORF72 amyotrophic lateral sclerosis (ALS)2.

Bioventus Inc., a global leader in innovations for active healing, announced that Ken M. Reali has stepped down as Chief Executive Officer and as a member of the Board of Directors.

Immuneering Corporation announced that it will hold a virtual Investor Event concurrent with a data presentation on its universal-RAS program IMM-1-104 at the American Association for Cancer Research Annual Meeting 2023.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the availability of a new webinar and white paper highlighting the T2Candida® Panel clinical data and best practices from real world use within Medical Intensive Care Units (MICU).

QSAM Biosciences Inc. (OTCQB: QSAM) today announces the opening of enrollment into the 2nd grouping of participants (Cohort 2) after completing Cohort 1 in February in its Phase 1 study evaluating CycloSam® in the treatment of bone cancer.